Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZ compound in NASH and NAFLD
NCT02605616Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitiperstat in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), sponsored by University of Alabama at Birmingham. Started Nov 2015; status: terminated.
02
Drugs
mitiperstat
03
Conditions
Nonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02605616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605616.